申请人:ZENTIVA KS
公开号:WO2019042485A1
公开(公告)日:2019-03-07
The solution relates to solid forms of roxadustat with the systematic name of (4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine of formula (I), methods of their preparation and use in a drug form. These solid forms of roxadustat of formula (I) are prepared by a reaction of roxadustat free acid with suitable coformers (inorganic or organic acids, bases, neutral molecules, or salts or ion pairs) in a suitable solvent or mixtures of solvents, the coformer is selected from the group consisting of meglumine, Ν,Ν'-dibenzylethylenediamine, tert-butylamine, diethylamine, dicyclohexylamine, ammonia, lithium, potassium hydroxide, calcium salt, magnesium salt, iron (III) salt, iron (II) salt, 2-naphtalenesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 3-ethyl-1 -methyl- 1H-imidazol-3-ium acetate and caffeine.
该解决方案涉及具有系统名称为(4-羟基-1-甲基-7-苯氧基异喹啉-3-羧基)甘氨酸的罗沙司他的固体形式,其化学式为(I),以及它们的制备方法和在药物形式中的使用。这些化学式为(I)的罗沙司他的固体形式是通过将罗沙司他游离酸与适当的配体(无机或有机酸、碱、中性分子、盐或离子对)在适当的溶剂或溶剂混合物中反应制备的,配体从以下组中选择:巯乙胺、Ν,Ν'-二苯基乙二胺、叔丁胺、二乙胺、二环己胺、氨、锂、氢氧化钾、钙盐、镁盐、铁(III)盐、铁(II)盐、2-萘磺酸、苯磺酸、对甲苯磺酸、3-乙基-1-甲基-1H-咪唑-3-ium 醋酸盐和咖啡因。